Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.

doi:10.1093/ehjcvp/pvae087

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.

European heart journal. Cardiovascular pharmacotherapy - 2 May 2025

van den Broek Wout Willem Antoon, Azzahhafi Jaouad, Chan Pin Yin Dean R P P, van der Sangen Niels M R, Sivanesan Shabiga, Dijksman Lea M, Walhout Ronald J, Tjon Joe Gin Melvyn, Breet Nicoline J, Langerveld Jorina, Vlachojannis Georgios J, van Bommel Rutger J, Appelman Yolande, van Schaik Ron H N, Henriques José P S, Kikkert Wouter J, Ten Berg Jurriën M

Abstract excerpt

AIMS: A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without affecting the effectivity of therapy by increasing ischaemic risk. We estimated the cost-effectiveness of this personalized approach compared to standard dual antiplatelet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Decision Trees

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Drug Substitution

Share to Models, Economic

Share to Prasugrel Hydrochloride

Share to Purinergic P2Y Receptor Antagonists

Share to Quality-Adjusted Life Years

Share to Ticagrelor

Source

Open in PubMed Open full text

Identifiers

PMID: 39537191
DOI: 10.1093/ehjcvp/pvae087
PMCID: PMC12046577

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.PMID 39537191Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

A Genotype-Guided P2Y12-Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence from the POPULAR-GUIDE PCISemantic proximity Read ↗

Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.Semantic proximity Read ↗

Genotype-Guided P2Y12-Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI.Semantic proximity Read ↗

The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.Semantic proximity Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.Semantic proximity Read ↗

Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular Genetics.Semantic proximity Read ↗

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.Semantic proximity Read ↗

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.Semantic proximity Read ↗

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.Semantic proximity Read ↗

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.